CareCost Prior authorization
Required
Check what the payer requires before you schedule Xolair.
Prior authorization · clinical prerequisites · quantity limits · site of care
28 of 30 payer policy sets hold an omalizumab policy · source-linked · reviewed August 2026
Aetna + allergic asthma is shown as a live example until you choose a payer.
This payer requires an approval on file before Xolair is purchased or administered for this member.
Precertification of omalizumab products is required of all Aetna participating providers and members in applicable plan designs
Covered under ICD-10 J45.
For treatment of moderate-to-severe asthma when all of the following criteria are met: Member is 6 years of age or older
What opens in CareCost
Aetna · Xolair · Allergic asthma
For every requirement: the exact payer criteria, the source citation, a check-off, and a save to the patient’s chart.
In CareCost: check off each requirement · save to the patient · print for the chart
Aetna · Xolair · Allergic asthma
You have already checked the policy, indication and covered dose. Open the remaining requirements and work them as a patient checklist.
CareCost tracks Xolair coverage requirements across 28 payer policy sets.
Aetna · Anthem / Elevance · Cigna · UnitedHealthcare · Regence · Premera · BCBS plans + more
Coverage clearance is only the first step.
CareCost carries the same patient through the entire workflow.
Finish this patient’s estimate →25 of 28 commercial payers with an omalizumab policy require prior authorization. The clinical prerequisite is diagnosis-specific: a controller-therapy trial for asthma, an up-dosed antihistamine trial for chronic urticaria, an intranasal-steroid trial for nasal polyps. Quantity limits, site-of-care rules and reauthorization terms vary by plan on top of it. Two payers CareCost has read, Arkansas BCBS and Kaiser Permanente WA, carry no omalizumab policy at all.
25 require PA · 411 clinical-prerequisite rules across four indications · 17 quantity-limit rules · 14 site-of-care rules · 4 reauthorization rules
Most commercial payers require approval before omalizumab is purchased or administered.
Coverage depends on the diagnosis in the payer’s omalizumab policy: allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, or IgE-mediated food allergy. Each carries its own prerequisite.
A trial of a different therapy first: an inhaled-corticosteroid combination for asthma, an up-dosed second-generation antihistamine for chronic urticaria, or an intranasal corticosteroid for nasal polyps. Food allergy has no comparable step; the label asks for continued allergen avoidance instead.
Asthma, nasal-polyp and food-allergy doses come off the label’s serum-IgE-by-weight table (75 to 375 mg for asthma, up to 600 mg for polyps and food allergy); chronic urticaria is a fixed 150 or 300 mg regardless of IgE or weight. A quantity limit written for one indication does not carry over to another.
Whether the injection has to happen in a health-care setting or can move to self-administration once the label’s criteria are met.
A handful of payers require renewed documentation on a schedule (every 12 months) or on evidence the patient is responding, rather than approving the drug once and leaving it open-ended.
Omalizumab covers four indications in CareCost’s corpus of 28 commercial payer policies, and the clinical prerequisite is different for each one: a controller-therapy trial for asthma, an up-dosed antihistamine trial for chronic urticaria, an intranasal-steroid trial for nasal polyps. Food allergy carries no comparable drug-trial step. Read the payer’s indication-specific language before assuming a prerequisite cleared for one diagnosis carries over to another.
| Indication | Payers with the indication | Typical prerequisite | Representative quote |
|---|---|---|---|
| Allergic asthma | 28 of 28 | Inadequate control on an optimized inhaled-corticosteroid combination | Aetna: “inadequate asthma control despite current treatment with both of the following medications at optimized doses” |
| Chronic spontaneous urticaria | 28 of 28 | Inadequate response to an up-dosed second-generation H1 antihistamine | Anthem: “an inadequate response to a two week trial of a second generation H1 antihistamine up dosed to a maximum of four times the approved dose” |
| Nasal polyps (CRSwNP) | 25 of 28 | Inadequate response to an intranasal corticosteroid | Anthem: “a trial and inadequate response to maintenance intranasal corticosteroids” |
| IgE-mediated food allergy | 24 of 28 | No drug-trial step; continued allergen avoidance instead | Label: not a treatment for anaphylaxis; the patient continues avoiding the allergen and carries epinephrine while on therapy |
Every commercial quantity limit CareCost has read tracks the dose ceiling already set in the label’s IgE-by-weight tables, not an arbitrary payer maximum: BCBS Nebraska caps chronic urticaria at “300 mg every 4 weeks; maximum 2 vials or 60 HCPCS units every 28 days” and asthma at “375 q 2 weeks”; Blue Shield of California writes the same three ceilings back into its policy (375 mg for asthma, 600 mg for polyps and food allergy, 300 mg for urticaria, each “every 2 or 4 weeks”); Capital BlueCross converts the ceilings to billable units: “75 billable units every 14 days” for asthma, “120 billable units every 14 days” for polyps and food allergy, “60 billable units every 28 days” for urticaria; Excellus caps urticaria doses so they “should not exceed 300mg per 4-week interval.” A claim above these ceilings is not under-dosing on the label. The label itself does not go higher.
Fourteen of the omalizumab rules CareCost has read turn on where, or by whom, the injection is given: not a hospital-versus-office distinction so much as an office-versus-home one. BCBS HCSC will cover self-administration or a caregiver-given dose only “after a minimum of three initial doses are given in a health care setting”; Horizon requires the drug to be “administered in an office/outpatient setting by a healthcare professional” for both asthma and chronic urticaria; Aetna and Regence apply a general site-of-care utilization policy to the product rather than a fixed rule; Premera frames it as routing “injection therapy of various medical or biologic agents” to “the most appropriate, safe and cost effective site.” Florida Blue’s site-of-care rule separately names Omlyclo, the one omalizumab biosimilar in this corpus; it carries no CMS payment limit in the ASP file this site reads, so it is named here only as a payer-referenced product, never with a rate.
Only 4 of the 28 payer policies CareCost has read set a renewal rule, and none of them ask for a repeat IgE test; the label itself says not to re-dose on IgE levels drawn during treatment. Capital BlueCross renews the authorization “every 12 months (365 days)”; BCBS Michigan asks only that “current criteria are met and that the medication is providing clinical benefit”; Centene ties asthma renewal to a measured adherence rate to controller therapy (“a proportion of days covered (PDC) of 0.8 in the last 6 months”) and ties chronic-urticaria renewal to the member “responding positively to therapy.”
No prior authorization for Part B omalizumab. Coverage follows the diagnosis codes in the Medicare policy. The governing local coverage determinations are published in the CMS Medicare Coverage Database, and a MAC can differ from its neighbour on the same drug.
This is the Original Medicare answer. A Medicare Advantage plan administers the same Part B benefit but can layer its own prior-authorization and site-of-care rules on top; check the plan’s own policy rather than assuming the Original Medicare rules below carry over.
CareCost has not read a Medicare local coverage determination naming omalizumab specifically for this corpus; where one governs in your MAC’s jurisdiction, its diagnosis and documentation requirements control instead of the general framing above. Check your MAC’s own LCD rather than assuming a neighbouring jurisdiction’s rule carries over.
The same self-administration question that shapes commercial site-of-care rules applies under Medicare: a dose given in the office stays on the medical benefit (J2357 plus 96372), while a dose the patient or caregiver injects at home typically moves to the drug plan instead, and the office visit and injection codes drop off the claim.
Payer citation language above is drawn from CareCost’s own omalizumab policy corpus (28 payers). Check the specific payer’s language →
It depends on the payer and plan. 25 of the 28 commercial omalizumab policies CareCost has read require prior authorization before Xolair is covered. Check this patient’s payer →
Xolair carries four covered indications in CareCost's omalizumab corpus: allergic asthma (28 of 28 payers), chronic spontaneous urticaria (28 of 28), chronic rhinosinusitis with nasal polyps (25 of 28) and IgE-mediated food allergy (24 of 28). Each indication carries its own prerequisite. Check coverage →
Either, once the payer's site-of-care rule is satisfied. The label allows self-administration after at least three in-office doses with no history of anaphylaxis; 14 of the omalizumab rules CareCost has read set conditions on where or by whom the injection is given. Check site of care →
Two things anchor most Xolair policies: the pre-treatment total IgE level and body weight that set the label's dose table, and the specific trial the payer names for this indication — controller therapy for asthma, an up-dosed antihistamine trial for chronic urticaria, or an intranasal corticosteroid trial for nasal polyps. CareCost turns the applicable payer policy into a patient-level checklist showing each requirement, what to confirm, and the source language supporting it. Open patient clearance →
Data current: payer policies Aug 2026 · reviewed dates come from each payer
Payer medical and specialty-drug policies · prior-authorization criteria · clinical-prerequisite and site-of-care rules · clinical coverage criteria. Medicare coverage from the CMS Medicare Coverage Database. Every CareCost requirement links back to its source policy.